- Email: [email protected]
CME POSTTEST
CME POSTTEST Please circle the correct answer. 1. By 2050, it is estimated that 1 in ___ Americans will have diabetes. A. B. C. D.
3 5 10 15
7. Compared with short-acting GLP-1 RAs (ie, exenatide twice a day), longer-acting GLP-1 RAs are associated with: A. B. C. D.
Greater A1C lowering potential Greater postprandial glucose reductions Less weight loss More nausea
2. Rates of diabetes are greatest in ____________ A. B. C. D.
African Americans Asian Americans Cuban Americans Mexican Americans
3. Which of the following may be used to diagnose type 2 diabetes? A. B. C. D.
A1C Z6.0% A random plasma glucose Z200 mg/dL Fasting plasma glucose (FPG) Z100 mg/dL Two-hour plasma glucose Z180 mg/dL during an OGTT
4. Which of the following is correct about current treatment algorithms for patients with type 2 diabetes? A. GLP-1 RAs and DPP4 inhibitors can be used in combination B. Greater emphasis is being placed on treatment options with low risks of hypoglycemia and weight gain C. Metformin is no longer the cornerstone of therapy D. Patients should move to combination therapy if monotherapy does not achieve glycemic goals in 6 months
8. Which GLP-1 RA is most like human GLP-1 in structure? A. B. C. D.
Exenatide Exenatide extended release Liraglutide Both A and B
9. GLP-1 RAs were associated with all of the following when compared with insulin EXCEPT? A. B. C. D.
More gastrointestinal adverse effects Less glucose-lowering effect Less hypoglycemia Less weight gain
10. Which of the following may be administered without regard to mealtimes? A. B. C. D. E.
Exenatide twice a day Exenatide extended release Liraglutide Both A and B Both B and C
5. Incretins are
11. Which of the following patients might NOT be a good candidate for incretin-based therapy?
A. B. C. D.
A. B. C. D.
Gastrointestinal hormones Precursors of glucagon Transporters of glucose in the kidney All of the above
Patient Patient Patient Patient
with with with with
Class II NYHA heart failure a history of pancreatitis osteoporosis short-duration disease
6. GLP-1 RAs and DPP-4 inhibitors are similar in what respects?
12. Liraglutide and exenatide extended release should not be prescribed in a patient with a history of:
A. B. C. D.
A. B. C. D.
Glucose-lowering efficacy Low risk of hypoglycemia Associated with weight loss Route of administration
Hepatitis C Lupus erythematosus Medullary cancer of the thyroid Multiple myeloma
CME EVALUATION FORM Educational Objectives How well did this activity meet the following learning objectives? Upon completion of this activity participants should be able to:
Not Met
Reinforcement
Moderate Improvement
Significant Improvement
Diagnose diabetes and select therapy for patients early in the course of disease Identify patients who would benefit from GLP -1 RA therapy and those for whom it may not be appropriate Explain to patients the efficacy, safety, and tolerability of GLP -1 RAs Develop appropriate combination therapy strategies and adjust doses of existing agents if needed Differentiate for patients GLP -1 RAs from DPP - 4 inhibitors and from insulin Compare and contrast short- and longacting GLP -1 RAs If “Not Met”, please explain for each objective _____________________________________________________________________________________________ _____________________________________________________________________________________________ _____________________________________________________________________________________________ _____________________________________________________________________________________________ How do you rate the relevance of the educational content to your daily practice? Not Relevant
Very Relevant
Was the information presented fair, objective, balanced, and free of bias in the discussion of any commercial product or service? Yes
No
If “No”, please describe _____________________________________________________________________________________________ _____________________________________________________________________________________________ _____________________________________________________________________________________________
Intent to Change Practice After participation in this activity, have you decided to change one or more aspects of your diagnostic approach to your patients? Yes
No
If “Yes”, what change(s) will you make? _____________________________________________________________________________________________ _____________________________________________________________________________________________ _____________________________________________________________________________________________ If “No”, why not? _____________________________________________________________________________________________ _____________________________________________________________________________________________ _____________________________________________________________________________________________
After participation in this activity, have you decided to change one or more aspects of treatment for your patients? Yes
No
If “Yes”, what change(s) will you make? _____________________________________________________________________________________________ _____________________________________________________________________________________________ _____________________________________________________________________________________________ If “No”, why not? _____________________________________________________________________________________________ _____________________________________________________________________________________________ _____________________________________________________________________________________________ Suggested topics for future activities _____________________________________________________________________________________________ _____________________________________________________________________________________________ _____________________________________________________________________________________________ Suggested authors/faculty for future activities _____________________________________________________________________________________________ _____________________________________________________________________________________________ _____________________________________________________________________________________________
Would you be willing to participate in medical education and post-activity surveys? Yes
No
Do you wish to be notified by email when new educational programs are offered by Elsevier? Yes
No
The EOCME thanks you for participation in this CME activity. All information provided improves the scope and purpose of our programs and your patient’s care.
3 5 10 15
7. Compared with short-acting GLP-1 RAs (ie, exenatide twice a day), longer-acting GLP-1 RAs are associated with: A. B. C. D.
Greater A1C lowering potential Greater postprandial glucose reductions Less weight loss More nausea
2. Rates of diabetes are greatest in ____________ A. B. C. D.
African Americans Asian Americans Cuban Americans Mexican Americans
3. Which of the following may be used to diagnose type 2 diabetes? A. B. C. D.
A1C Z6.0% A random plasma glucose Z200 mg/dL Fasting plasma glucose (FPG) Z100 mg/dL Two-hour plasma glucose Z180 mg/dL during an OGTT
4. Which of the following is correct about current treatment algorithms for patients with type 2 diabetes? A. GLP-1 RAs and DPP4 inhibitors can be used in combination B. Greater emphasis is being placed on treatment options with low risks of hypoglycemia and weight gain C. Metformin is no longer the cornerstone of therapy D. Patients should move to combination therapy if monotherapy does not achieve glycemic goals in 6 months
8. Which GLP-1 RA is most like human GLP-1 in structure? A. B. C. D.
Exenatide Exenatide extended release Liraglutide Both A and B
9. GLP-1 RAs were associated with all of the following when compared with insulin EXCEPT? A. B. C. D.
More gastrointestinal adverse effects Less glucose-lowering effect Less hypoglycemia Less weight gain
10. Which of the following may be administered without regard to mealtimes? A. B. C. D. E.
Exenatide twice a day Exenatide extended release Liraglutide Both A and B Both B and C
5. Incretins are
11. Which of the following patients might NOT be a good candidate for incretin-based therapy?
A. B. C. D.
A. B. C. D.
Gastrointestinal hormones Precursors of glucagon Transporters of glucose in the kidney All of the above
Patient Patient Patient Patient
with with with with
Class II NYHA heart failure a history of pancreatitis osteoporosis short-duration disease
6. GLP-1 RAs and DPP-4 inhibitors are similar in what respects?
12. Liraglutide and exenatide extended release should not be prescribed in a patient with a history of:
A. B. C. D.
A. B. C. D.
Glucose-lowering efficacy Low risk of hypoglycemia Associated with weight loss Route of administration
Hepatitis C Lupus erythematosus Medullary cancer of the thyroid Multiple myeloma
CME EVALUATION FORM Educational Objectives How well did this activity meet the following learning objectives? Upon completion of this activity participants should be able to:
Not Met
Reinforcement
Moderate Improvement
Significant Improvement
Diagnose diabetes and select therapy for patients early in the course of disease Identify patients who would benefit from GLP -1 RA therapy and those for whom it may not be appropriate Explain to patients the efficacy, safety, and tolerability of GLP -1 RAs Develop appropriate combination therapy strategies and adjust doses of existing agents if needed Differentiate for patients GLP -1 RAs from DPP - 4 inhibitors and from insulin Compare and contrast short- and longacting GLP -1 RAs If “Not Met”, please explain for each objective _____________________________________________________________________________________________ _____________________________________________________________________________________________ _____________________________________________________________________________________________ _____________________________________________________________________________________________ How do you rate the relevance of the educational content to your daily practice? Not Relevant
Very Relevant
Was the information presented fair, objective, balanced, and free of bias in the discussion of any commercial product or service? Yes
No
If “No”, please describe _____________________________________________________________________________________________ _____________________________________________________________________________________________ _____________________________________________________________________________________________
Intent to Change Practice After participation in this activity, have you decided to change one or more aspects of your diagnostic approach to your patients? Yes
No
If “Yes”, what change(s) will you make? _____________________________________________________________________________________________ _____________________________________________________________________________________________ _____________________________________________________________________________________________ If “No”, why not? _____________________________________________________________________________________________ _____________________________________________________________________________________________ _____________________________________________________________________________________________
After participation in this activity, have you decided to change one or more aspects of treatment for your patients? Yes
No
If “Yes”, what change(s) will you make? _____________________________________________________________________________________________ _____________________________________________________________________________________________ _____________________________________________________________________________________________ If “No”, why not? _____________________________________________________________________________________________ _____________________________________________________________________________________________ _____________________________________________________________________________________________ Suggested topics for future activities _____________________________________________________________________________________________ _____________________________________________________________________________________________ _____________________________________________________________________________________________ Suggested authors/faculty for future activities _____________________________________________________________________________________________ _____________________________________________________________________________________________ _____________________________________________________________________________________________
Would you be willing to participate in medical education and post-activity surveys? Yes
No
Do you wish to be notified by email when new educational programs are offered by Elsevier? Yes
No
The EOCME thanks you for participation in this CME activity. All information provided improves the scope and purpose of our programs and your patient’s care.